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The COVID-19 pandemic is caused by severe acute respiratory syn-
drome coronavirus-2 (SARS-CoV-2) and has spread worldwide,
with millions of cases and more than 1 million deaths to date.
The gravity of the situation mandates accelerated efforts to iden-
tify safe and effective vaccines. Here, we generated measles virus
(MeV)-based vaccine candidates expressing the SARS-CoV-2 spike
glycoprotein (S). Insertion of the full-length S protein gene in two
different MeV genomic positions resulted in modulated S protein
expression. The variant with lower S protein expression levels
was genetically stable and induced high levels of effective Th1-
biased antibody and T cell responses in mice after two immuni-
zations. In addition to neutralizing IgG antibody responses in a
protective range, multifunctional CD8+ and CD4+ T cell responses
with S protein-specific killing activity were detected. Upon chal-
lenge using a mouse-adapted SARS-CoV-2, virus loads in vacci-
nated mice were significantly lower, while vaccinated Syrian
hamsters revealed protection in a harsh challenge setup using
an early-passage human patient isolate. These results are highly
encouraging and support further development of MeV-based
COVID-19 vaccines.
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Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs to Coronaviridae family and emerged to-
ward the end of 2019 as causative agent of pneumonia in the
Hubei province in China (1). The World Health Organization
named the disease Corona Virus Disease-2019 (COVID-19),
and officially declared the pandemic state on March 11, 2020.
Human coronaviruses have been known for decades as one of
the causative agents of the common cold, but two previous
coronavirus outbreaks, caused by the severe acute respiratory
syndrome virus (SARS-CoV-1) and the Middle East respiratory
syndrome virus (MERS-CoV), have demonstrated the re-
markable pathogenic potential of human beta coronaviruses.
Around 10,000 people have been infected by SARS and MERS,
which has resulted in a death toll of about 1,500 patients, but
the outbreaks remained largely confined in terms of time or
spread, respectively. In contrast, SARS-CoV-2 spreads effec-
tively and at a rapid pace by direct transmission, with a re-
productive number R0 of at least 2 to 2.5 (2, 3). Due to high
transmissibility and extensive community spread, this novel
coronavirus has already caused over 36.2 million infections and
over 1 million deaths (as of October 9, 2020; https://www.who.
int/emergencies/diseases/novel-coronavirus-2019), while worldwide
shutdowns of social life and economy to confine the spread of
this respiratory virus have considerable impacts.
After the emergence of SARS in 2002 and then MERS in
2012, vaccine development efforts have been initiated, includ-
ing the use of recombinant measles virus (MeV) vaccine as a
platform concept (4), to develop vector vaccine candidates
against both agents, and showed promising results. Recombinant
MeV vectors encoding the unmodified SARS-CoV Spike protein
induced high titers of neutralizing antibodies as well as IFN-γ
T cell responses (5, 6) and conferred protection to immunized
animals upon pathogen challenge by lowering virus titers more
than 100-fold (5). For MERS, we have demonstrated that high
titers of neutralizing antibodies as well as effective and poly-
functional T cell responses were induced in vaccinated animals
(7, 8) and conferred protection (7). Based on these data, an
MeV-based MERS vaccine candidate has been selected by the
Coalition for Epidemic Preparedness Initiative for further clinical
development (http://www.cepi.net/research_dev/our-portfolio).
Here, we explored the potential of recombinant MeV as vec-
tors for the expression of the SARS-CoV-2 spike protein (S) as
successfully applied for the development of MERS (7, 8) and
SARS (5, 6) vaccine candidates, as well as numerous other path-
ogens (4). The S glycoprotein was chosen as antigen for its role as
primary target of neutralizing antibodies (6, 7) and the exemplary
capability of MERS-CoV S protein to trigger strong cell-mediated
immune responses when expressed by MeV in our front-runner
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MERS vaccine candidate (7, 8). The SARS-CoV-2 S protein-
encoding gene was inserted into two different positions of the
MeV genome to modulate antigen expression, and both recombi-
nant MeVs were successfully rescued. The virus expressing lower S
protein levels resulted in stable amplification over at least 10
passages, while impairment of replication was insignificant. Indeed,
immunization of IFNAR−/−-CD46Ge mice induced strong and
functional humoral and cellular immune responses directed against
both MeV and SARS-CoV-2 S protein biased for Th1-type T cell
and antibody responses. The induced immunity translated in an-
tiviral efficacy in two different challenge models, that is, vaccinated
hamsters and mice, thereby illustrating the potential of MeV
platform-based COVID-19 vaccine candidates.
Results
Generation and Characterization of SARS-CoV-2-S by Recombinant
MeVvac2. Since the SARS-CoV and MERS-CoV S proteins have
been shown to potently induce humoral and cellular immune
responses, the SARS-CoV-2 S protein was chosen as an appro-
priate antigen to be expressed by the recombinant MeV vaccine
platform. A codon-optimized full-length gene encoding SARS-
CoV-2 S protein was cloned into two different additional tran-
scription units (ATUs) in the vaccine strain MeVvac2 genome,
either downstream of the P (post P) or H (post H) gene cassettes
(Fig. 1A). Recombinant viruses were successfully generated and
amplified up to P10 in Vero cells with titers of up to 4 × 107 50%
tissue culture infectious doses (TCID50)/mL. The stability of the
viral genomes was demonstrated via sequencing after RT-PCR
of viruses in P2 or P10. In parallel to Sanger sequencing of the
ATU region encompassing the SARS-CoV-2-S gene, the full
genome was sequenced using next-generation sequencing (NGS)
with a coverage of 4 to 29,683 reads of each position (SI Ap-
pendix, Fig. S1) in P2. Both methods revealed no mutations
across the whole vaccine genomes but a single A to G substitu-
tion on position 9 of the noncoding trailer region of the MeVvac2-
SARS2-S(H) clone used for in vivo studies (GenBank accession
no. MW090971).
To verify SARS-CoV-2 S protein expression levels, Western
blot analysis of Vero cells infected with the MeVvac2-SARS2-S
was performed. The S protein expression was slightly attenuated
when cells were infected with viruses encoding the antigen in the
ATU post-H compared to the post-P constructs (Fig. 1B).
However, there was less overall viral protein expression in cells
infected with post-P construct. Comparative growth kinetics with
the vaccine viruses containing the SARS-CoV-2 S gene and the
MVvac2-ATU(P) control virus revealed that the MeVvac2 encoding
full-length SARS-CoV-2 S gene in post-P position grew remark-
ably different than the control virus, with ∼100-fold reduced
maximal titers. In contrast, growth of MeVvac2-SARS2-S(H) was
much closer to MVvac2-ATU(P), with only a slight trend for lower
titers (Fig. 1 C and D).
The impaired growth of MeVvac2-SARS2-S(P) was accompa-
nied by a hyperfusogenic phenotype (Fig. 1E and SI Appendix,
Fig. S2A), which was also observed for the post-H vaccine can-
didate, but to a lesser extent. Therefore, fusion activity was quan-
tified and compared to the parental MVvac2-ATU(P) as well as the
MVNSe-GFP(N), which is known for its hyperfusogenic phenotype
due to a V94M substitution in the F2 subunit of the MeV fusion
protein (9). MVvac2-ATU(P) induced fusion of 16.8 ± 0.8 (mean±
SD) Vero cells 30 h after infection. MeVvac2-SARS2-S(P) revealed
approximately fourfold enhanced fusion activity (syncytia includ-
ing 70 ± 8 cells), while MeVvac2-SARS2-S(H) just fused 41 ± 6
cells, thereby representing an intermediate phenotype. However,
fusion activity of the latter was surpassed by MVNSe-GFP(N) that
fused 56 ± 4 cells in 30 h under the same conditions (SI Appendix,
Fig. S2B).
To investigate whether this increased fusion activity is due to
SARS-CoV-2 S protein-mediated cell-to-cell fusion, we expressed
the SARS-CoV-2 S protein by transfection of the eukaryotic ex-
pression plasmid pcDNA3.1-SARS2-S into SARS-CoV-2 receptor
hACE2-negative 293T as well as into receptor-positive Vero cells.
Indeed, expression of SARS-CoV-2 S protein induced syncytia of
Vero, but not of 293T cells (SI Appendix, Fig. S3).
These data demonstrate that the hyperfusogenic phenotype of
the SARS-CoV-2 S-encoding MeV is linked to expression of a
fusion-active form of the SARS-CoV-2 S protein, indicating that
cells infected by the vaccine candidates express a functional S
protein. Thus, cloning and rescue of MeVs expressing correctly
folded SARS-CoV-2 S was achieved successfully. Since higher S
protein expression levels impaired viral replication, MeVvac2-
SARS2-S(H) was chosen for further characterization in vivo.
MeVvac2-SARS2-S(H) Induces Neutralizing Antibodies against MeV and
SARS-CoV-2. To test the efficacy of MeVvac2-SARS2-S(H) in vivo,
genetically modified IFNAR−/−-CD46Ge mice were used, since
they are the prime small animal model for analysis of MeV-
derived vaccines (10). Groups of six to seven animals were im-
munized via the intraperitoneal route on days 0 and 28 with 1 ×
105 TCID50 of MeVvac2-SARS2-S(H) or empty MVvac2-ATU(P)
as a control. As positive control, recombinant SARS-CoV-2 S
protein adjuvanted with aluminum hydroxide gel (Alum) was
injected subcutaneously, and medium-inoculated mice served as
mock controls. Twenty-one days after the second immunization,
sera of immunized mice were analyzed in comparison to pre-
bleed and postprime immunization sera, by ELISA on antigen-
coated plates, for total IgG antibodies binding to MeV bulk
antigens (Fig. 2 G–I) or SARS-CoV-2 S protein (Fig. 2 A–C).
Sera of mice vaccinated with MeVvac2-SARS2-S(H) contained
IgG antibodies that bound to SARS-CoV-2 S protein (Fig. 2 B
and C), whereas no antibodies were found in mice before vac-
cination (Fig. 2A), or in MeV or mock-immunized control mice.
Moreover, final sera of mice vaccinated with any recombinant
MeV had IgG in the serum binding to MeV bulk antigens, in-
dicating at least one successful vaccination with MeVs and
general vector immunogenicity (Fig. 2 G–I). The control S pro-
tein vaccine did induce higher levels of S protein-binding IgG
than MeVvac2-SARS2-S(H) (Fig. 2C).
We next determined the neutralizing antibody responses
against SARS-CoV-2 (Fig. 2 D–F) or MeV (Fig. 2 J–L). Most
mice immunized with recombinant MeV, including those receiving
the control virus, had developed MeV neutralizing antibody titers
(virus neutralization titer [VNT]) after the first immunization
(Fig. 2K). However, two mice of the MeVvac2-SARS2-S(H) cohort
initially reacted only weakly, and another mouse reacted not at all,
reflecting individual differences in response to immunization. All
animals had developed neutralizing antibodies after the second
immunization, and a threefold increase was observed upon the
second immunization (220 to 762 VNT; Fig. 2 K and L). Neu-
tralizing antibodies against SARS-CoV-2 were detected in mice
vaccinated with MeVvac2-SARS2-S(H) after the second immuni-
zation, and reached a titer of 15 to 80 in three out of seven mice
(Fig. 2F). These titers were in the range of human reconvalescent
sera tested in parallel (VNT 10 to 60; SI Appendix, Fig. S4). No
VNTs against MeV or SARS-CoV-2 were detected in control
mice inoculated with medium alone. Interestingly, the Alum-
adjuvanted recombinant S protein did not induce any neutraliz-
ing antibodies despite higher binding IgG levels in ELISA, indi-
cating that these antibodies bind to other epitopes of S or with
lower affinity than those induced by the MeV-based vaccine
candidate. In summary, the SARS-CoV-2 S protein-expressing
MeV elicited robust neutralizing antibody responses against
MeV and SARS-CoV-2.
Splenocytes of Animals Vaccinated with MeVvac2-SARS2-S(H) React to
SARS-CoV-2 S Protein-Specific Stimulation. To assess the ability of
MeVvac2-SARS2-S(H) to induce SARS-CoV-2−specific cellular
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immune responses, splenocytes of vaccinated animals were an-
alyzed for antigen-specific IFN-γ secretion by Enzyme-Linked
Immunosorbent Spot (ELISpot) assay. Toward this, antigen-
specific T cells were restimulated by cocultivation with the syn-
geneic murine dendritic cell (DC) cell lines JAWSII or DC2.4
stably expressing the SARS-CoV-2 S protein. For JAWSII cells,
bulk cultures of transduced cells were obtained by flow cyto-
metric sorting. For DC2.4 cells, single-cell clones were generated
by limiting dilution of sorted bulk cultures. Antigen expression by
transduced DCs was verified by Western blot analysis and flow
cytometry (SI Appendix, Fig. S5).
ELISpot assays using splenocytes of vaccinated animals in
coculture with DC2.4-SARS2-S cells revealed more than
1,400 IFN-γ secreting cells per 1 × 106 splenocytes after immu-
nization with MeVvac2-SARS2-S(H) (Fig. 3). In contrast, cocul-
ture with splenocytes of control mice resulted in a background
response of less than 50 IFN-γ producing cells per 1 × 106
splenocytes. As expected, restimulation of T cells by DC2.4 pre-
senting no exogenous antigen revealed only reactivity in the range
of background (Fig. 3). To rule out clonal or cell line-associated
artifacts, antigen-specific IFN-γ secretion by splenocytes of
MeVvac2-SARS2-S(H)−vaccinated mice was confirmed by stimu-
lation with transgenic JAWSII-SARS2-S bulk cells. These cells
also stimulated in excess of 1,400 IFN-γ secreting cells per 1 × 106
splenocytes in animals receiving the recombinant SARS-CoV-2
vaccines, whereas only slight background stimulation was observed
by the respective controls. The differences between MeV control
and MeVvac2-SARS2-S(H) vaccinated mice were statistically sig-
nificant for both cell lines. Mice vaccinated with Alum-adjuvanted
S protein showed no specific reactivity in IFN-γ ELISpot.
Cellular immune responses upon stimulation with MeV bulk
antigens were detected in animals that had been vaccinated with
any recombinant MeV virus, as expected. While MeV bulk an-
tigens stimulated about 300 to 1,400 IFN-γ secreting cells per 1 ×
106 splenocytes of MVvac2-ATU(P)−vaccinated animals, sple-
nocytes of MeVvac2-SARS2-S(H)−vaccinated animals were in a
similar range of 400 to 1,400 IFN-γ secreting cells per 1 ×
106 splenocytes. Splenocytes of all animals revealed a similar
basic reactivity to unspecific T cell stimulation, as confirmed by
numbers of IFN-γ secreting cells upon concanavalin A (ConA)
treatment at the limit of detection. Remarkably, stimulation of
splenocytes by DC2.4 expressing SARS-CoV-2-S resulted in at
Fig. 1. Generation and in vitro characterization of MeVvac2-SARS2-S(P) and MeVvac2-SARS2-S(H). (A) Schematic depiction of full-length SARS-CoV-2 S and
recombinant MeVvac2 genomes used for expression of this antigen (lower schemes). Antigens or antigen-encoding genes are depicted in dark gray; MeV viral
gene cassettes (in light gray) are annotated. MluI and AatII restriction sites used for cloning of antigen genes into post-P or post-H ATU are highlighted. (B)
Immunoblot analysis of Vero cells infected at an MOI of 0.01 with MeVvac2-SARS2-S(P), MeVvac2-SARS2-S(H), or MVvac2-ATU(P) (MVvac2) as depicted above
lanes. Uninfected cells served as mock. Blots were probed using rabbit polyclonal anti-SARS spike antibody (upper blot) or mAb reactive against MeV-N (lower
blot). Arrows indicate specific bands. (C and D) Growth kinetics of recombinant MeV on Vero cells infected at an MOI of 0.03 with MVvac2-ATU(P) or MeVvac2-
SARS2-S encoding extra genes in post H or post P. Titers of samples prepared at indicated time points postinfection (days post infection, dpi) were titrated on
Vero cells. Means and SDs of three to five independent experiments are presented. (E) SARS-CoV-2 S protein expression in Vero cells was verified via
immunoperoxidase monolayer assay; 50× magnification. (Scale bar, 500 μm.)









least similar or even higher numbers of IFN-γ+ cells than after
stimulation by MeV bulk antigens, indicating an extremely ro-
bust induction of cellular immunity against this antigen. Taken
together, these data show that MeVvac2-SARS2-S(H) induces
not only humoral but also strong SARS-CoV-2 S protein-specific
cellular immune responses.
SARS-CoV-2 S-Reactive T Cells Are Multifunctional. To gain more
detailed insights into the quality of the observed T cell responses,
we further characterized the responsive T cell populations by
flow cytometry, determining the expression of IFN-γ, TNF-α, and
IL-2 in CD8+ and CD4+ positive CD3+ T cells upon restimulation
with SARS-CoV-2 S-presenting DC2.4-SARS2-S cells by intracel-
lular cytokine staining (ICS). As a positive stimulus for T cell ac-
tivation, ionomycin and phorbol myristate acetate (Ionomycin/
PMA) were used. Exocytosis of cytokines was blocked by addition
of brefeldin A (10 μg/mL) during stimulation. Cells were per-
meabilized, labeled, and fixed for flow cytometry. The gating
strategy excluded duplicates (SI Appendix, Fig. S6, Middle, first
row), selected for living cells (SI Appendix, Fig. S6, Right, first row),
and separated CD8+ and CD4+ T cells on CD3+ cell populations
(SI Appendix, Fig. S6, second row). Selected T cells were then
analyzed for their expression of IFN-γ, TNF-α, or IL-2, double-
positive (SI Appendix, Fig. S6, third row), or triple-positive (SI
Appendix, Fig. S4, fourth row) cells as exemplarily shown for CD4+
T cells after restimulation with PMA and ionomycin (SI Appendix,
Fig. S6).
Vaccination with MeVvac2-SARS2-S(H) induced a significant
amount of SARS-CoV-2 S-specific CD8+ T cells expressing ei-
ther IFN-γ (Fig. 4 B, Left), IL-2 (Fig. 4 B, Middle), or TNF-α
(Fig. 4 B, Right), with means between 0.02% and 0.5% of positive
cells for each of these cytokines. Among those, a significant
fraction of cells proved to be multifunctional, with a mean of
47% of the reactive CD8+ cells expressing two cytokines or 13%
of responsive CD8+ cells being positive for TNF-α, IL-2, and
IFN-γ (SI Appendix, Fig. S7). A much lower portion of respon-
sive CD4+ T cells was observed, varying between 0.01% and
0.07% of CD4+ T cells. Among the responsive CD4+ cells, 40%
expressed two cytokines and 11% were positive for TNF-α, IL-2,
and IFN-γ. Moreover, vaccination induced a significant fraction
of vector-specific CD4+ T cells expressing IFN-γ (Fig. 4 A, Left),
IL-2 (Fig. 4 A, Middle), or TNF-α (Fig. 4 A, Right) upon restim-
ulation with MeV bulk antigen. Among those, multifunctional
CD4+ T cells expressing two or all three cytokines were induced
with a mean of about 23% and 6% polyreactive T cells (SI Ap-
pendix, Fig. S7), respectively. To conclude, vaccination with MeV-
vac2-SARS2-S(H) induces not only IFN-γ, TNF-α, or IL-2 expressing
T cells directed against SARS-CoV-2 andMeV but also a significant
fraction of multifunctional cytotoxic T cells specific for SARS-
CoV-2 S and CD4+ T cells specific for MeV antigens, illustrating
Fig. 2. Induction of α-SARS-CoV-2 S and α-MeV specific antibodies. Sera of mice vaccinated on days 0 and 28 with indicated viruses or Alum-adjuvanted S
protein were sampled on day 0 (A, D, E, F), day 28 after prime immunization (B, E, H, K), and day 49 after boost immunization (C, F, I, L) and analyzed for
antibodies specific for SARS-CoV-2 S or MeV. Medium-inoculated mice served as mock. Pan-IgG binding to recombinant SARS-CoV-2 S (A–C) or MeV bulk
antigens (G–I) were determined by ELISA via the specific optical density (OD) 450 nm value. Depicted are means and respective SD of the mean (SEM) of each
group (n = 5 to 7). VNT in vaccinated mice for SARS-CoV-2 (D–F) or MeV (J–L) were calculated as reciprocal of the highest dilution abolishing infectivity.
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that a broad and robust SARS-CoV-2−specific immune response is
induced by vaccination with MeVvac2-SARS2-S(H).
The reactivity of these T cells also became apparent in a pro-
liferative response to antigen-specific stimulation. Using carboxy-
fluorescein succinimidyl ester (CFSE)-labeled splenocytes and
flow cytometry, we detected significant proliferation of both CD4+
and CD8+ T cells upon stimulation with S-presenting DCs only
among the splenocytes of MeVvac2-SARS2-S(H)−vaccinated ani-
mals (SI Appendix, Fig. S8).
Induced T Cells Reveal Antigen-Specific Cytotoxicity. To demon-
strate the effector ability of induced cytotoxic T lymphocytes
(CTLs), a killing assay was performed to directly analyze antigen-
specific cytotoxicity (Fig. 5). Splenocytes of immunized mice iso-
lated 21 d post boost vaccination were cocultured with DC2.4-
SARS2-S or parental DC2.4 cells for 6 d to restimulate antigen-
specific T cells. When these restimulated T cells were coincubated
with a defined mixture of EL-4green-SARS2-S target and EL-4red
control cells (ratio ∼1:1), only T cells from MeVvac2-SARS2-
S(H)−vaccinated mice significantly shifted the ratio of live
SARS-CoV-2 S protein-expressing target cells to control cells in a
dose-dependent manner (Fig. 5B). This antigen-dependent killing
was also dependent on restimulation with DC2.4-SARS2-S cells,
since unstimulated T cells did not significantly shift the ratios of
target to nontarget cells (Fig. 5A).
These results indicate that CTLs isolated from MeVvac2-
SARS2-S(H)−vaccinated mice are capable of lysing cells express-
ing SARS-CoV-2 S. Neither splenocytes of control mice restimu-
lated with DC2.4-SARS2-S nor splenocytes of SARS-CoV-2 S
protein vaccinated mice restimulated with control DC2.4 cells
showed such an antigen-specific killing activity, demonstrating that
MeVvac2-SARS2-S(H) induces fully functional antigen-specific
CD8+ CTLs.
Induced Immunity Is Skewed toward Th1-Biased Responses. While
the functionality of both humoral and cellular anti-SARS-CoV-2
immune responses elicited by MeVvac2-SARS2-S(H) is reassur-
ing, the SARS-CoV-2 vaccine development has to proceed with
some caution because of the potential risk of immunopatho-
genesis observed in some animal models, such as antibody-
dependent enhancement (ADE) and enhanced respiratory dis-
ease (ERD) which seem to correlate with a Th2-biased immune
response. Since, in mice, IgG1 is a marker for Th2 bias and risk
of ADE development, whereas IgG2a antibodies indicate a fa-
vorable Th1 bias, IgG subtype-specific ELISA was performed
with the sera collected at different time points. Animals vacci-
nated with Alum-adjuvanted SARS-CoV-2 S protein, a vaccine
concept known for its Th2 bias (11, 12), developed high levels of
Fig. 3. Secretion of IFN-γ after antigen-specific restimulation of sple-
nocytes. IFN-γ ELISpot analysis using splenocytes of mice vaccinated
on days 0 and 28 with indicated vaccines, isolated 21 d after boost im-
munization, and after coculture with DC2.4 or JAWSII dendritic cell lines
transgenic for SARS-CoV-2 S (SARS2-S) or untransduced controls (untr.).
To analyze cellular responses directed against MeV, splenocytes
were stimulated with 10 μg/mL MeV bulk antigens or were left unsti-
mulated as controls (medium). The reactivity of splenocytes was con-
firmed by ConA treatment (10 μg/mL). The number of cells per 1 × 106
splenocytes represents the amount of cells expressing IFN-γ upon
restimulation. Dots represent individual animals; horizontal bars are
mean per group (n = 6 to 7). Samples above the upper detection limit
(ULOD) were displayed as such. For statistical analysis of grouped
ELISpot data, two-way ANOVA analysis was applied with paired Tukey’s
multicomparison test used as post hoc test; ns, not significant; (P > 0.05);
**P < 0.01; ****P < 0.0001.
Fig. 4. Detection of multifunctional T-cell responses induced by vaccination with MeVvac2-SARS2-S(H). Harvested splenocytes of MeVvac2-SARS2-
S(H)−vaccinated mice (same as depicted in Fig. 3) were restimulated and subjected to intracellular staining (ICS) for IFN-γ (Left), TNF-α (Right), and IL-2
(Middle), and stained for extracellular T-cell markers CD3, CD4, and CD8 for flow cytometry analysis. Quantification of flow cytometry data of (A) CD4+-
and (B) CD8+-positive T cells after coculture with antigen-presenting DC2.4-SARS2-S or parental DC2.4 control cells, or after incubation with indicated
stimuli (MeV bulk antigen [MeV bulk], or untreated cells [mock]); reactivity of splenocytes was confirmed by Ionomycin/PMA treatment (10 μg/mL). Dots
represent individual animals; horizontal bars are mean. Mann−Whitney test was used to compare cytokines levels between DC2.4 and DC2.4-SARS2-S
restimulated splenocytes in the MeVvac2-SARS2-S(H) vaccine group without correction for multiple testing, because of the exploratory character of the
study. *P < 0.05; **P < 0.01.









S protein-specific IgG1 antibodies, whereas few S-specific IgG2a
antibodies were detected (Fig. 6A). In comparison, MeVvac2-
SARS2-S(H) induced 100-fold fewer IgG1 antibodies, but at
least 10-fold higher IgG2a levels (Fig. 6A), indicating a favorable
Th1 bias in animals immunized with the MeV-derived vaccine
candidate.
These findings were confirmed by multiplex cytokine analysis
of the cytokine profile in the supernatants of splenocytes from
vaccinated animals, which were restimulated using DC2.4 or
DC2.4-SARS2-S cells. All splenocytes of representative ani-
mals revealed secretion of all cytokines after stimulation with
ConA, demonstrating general reactivity of cells and assay (SI
Appendix, Fig. S9). Most likely due to the low number of
S-reactive T cells in animals that had been vaccinated with
recombinant SARS-CoV-2 S protein and Alum, no, or minimal,
constant cytokine levels were measurable in the supernatants of
restimulated splenocytes (Fig. 6B). In contrast, splenocytes of
animals immunized with MeVvac2-SARS2-S(H) reacted spe-
cifically with the secretion of IFN-γ, TNF-α, and IL-2 upon
restimulation by DC2.4-SARS2-S (Fig. 6B), in accordance with
ELISpot (Fig. 3) and ICS data (Fig. 4). However, we could
observe no or minimal up-regulation of IL-4, IL-5, IL-13, or IL-
10, which would have been indicative for a Th2-biased response
(Fig. 6B). Also, IL-17a or IL-6 indicative of a Th17 or general
inflammatory response, respectively, showed minimal changes
(Fig. 6B).
Thus, both humoral and cellular responses reveal a Th1-biased
immunity induced by MeVvac2-SARS2-S(H), which indicates a
relatively low risk for putatively Th2-mediated immunopathologies.
MeV-COVID-19 Vaccine-Induced Immune Responses Are Effective In
Vivo. To finally test antiviral efficacy and the protective capac-
ity of the immune responses induced by our COVID-19 vaccine
candidate, two different animal models of COVID-19 were used.
On the one hand, we established the Syrian golden hamster
model for SARS-CoV-2−induced disease, which revealed re-
markably severe outcome. Using an available low-passage SARS-
CoV-2 patient isolate for intranasal challenge of 6- to 12-wk-old
hamsters, the infected animals developed severe pneumonia with
an impressive gross pathology (SI Appendix, Fig. S10 A and B) that
necessitated killing four out of six animals within 5 d to 6 d
postinfection (SI Appendix, Fig. S10C). To take advantage of this
model, hamsters were vaccinated with MeVvac2-SARS2-S(H),
MVvac2-ATU(H) as vector control, Alum-adjuvanted SARS-CoV-
2 Spike protein as vaccine control, or medium (mock) in a pri-
me−boost scheme for challenge. These hamsters showed induc-
tion of anti-MeV and anti-SARS-CoV-2 humoral immune responses
with neutralizing antibody titers against SARS-CoV-2 between 15
and 80 VNT corresponding to 20 to 213 PRNT50 (50% plaque
reduction neutralization titer), exceeding those of the Alum-S
vaccine control group (SI Appendix, Fig. S11 F and M). Upon
challenge, the initial weight loss observed in all groups was stop-
ped in the MeVvac2-SARS2-S(H) cohort on day 3 postinfection,
and animals started to gain weight, whereas all other groups
revealed progressive weight loss (Fig. 7A). The experiment was
stopped 4 d postinfection to determine live virus titers (Fig. 7B) as
well as virus genome copy numbers (Fig. 7C) in relevant tissues,
that is, lungs and nasal turbinates. The corresponding data
reflected the observations on gross pathology (Fig. 7A and SI
Appendix, Fig. S12): The hamsters vaccinated with MeVvac2-
SARS2-S(H) had a more than 10-fold reduction in virus genomes
in lungs and nasal turbinates than all other groups (Fig. 7C),
corresponding to absence of live virus in the lungs of five out of six
and nasal turbinates of one out of six vaccinated animals (Fig. 7B).
Thus, vaccination with MeVvac2-SARS2-S(H) significantly ame-
liorated virus loads in infected animals and protected them against
severe pathology in this remarkably aggressive challenge model.
In this model, SARS-CoV-2 neutralization antibody titers in
MeVvac2-SARS2-S(H)−vaccinated hamsters showed a tendency
to reversely correlate with weight loss and RNA copy numbers in
lung and nasal turbinates, indicating some role of neutralizing
antibodies in fighting disease progression (Fig. 7D).
Our second animal model confirmed these observations. Virus
loads of the mouse-adapted SARS-CoV-2 MA (13) were sig-
nificantly reduced in the lungs of vaccinated mice (corresponding
immunity data in SI Appendix, Fig. S13), and revealed a tendency
for reduced titers in nasal turbinates, as well (Fig. 7E), in the
absence of gross pathology in both groups. Therefore, both chal-
lenge models show protective efficacy of the immune responses
induced by MeVvac2-SARS2-S(H).
Discussion
In this study, we aimed to analyze the efficacy of MeV-derived
vaccine candidates encoding the Spike glycoprotein S of
SARS-CoV-2 to induce functional immune responses to protect
against COVID-19. We show that MeVvac2-SARS2-S(H) repli-
cated comparably to MeV vaccine strain viruses and was genet-
ically stable over extended passaging. Upon vaccination of mice,
it induced robust humoral immune responses of the IgG2a
subtype directed against the SARS-CoV-2 spike glycoprotein S
with neutralizing activity in a range already shown to be protective
by others. In addition, considerable amounts of SARS-CoV-2
S-specific CD4+ and CD8+ T cells were induced, the major frac-
tion of which were secreting two or even all three cytokines when
analyzing for IFN-γ, TNF-α, or IL-2 upon antigen-specific
restimulation. These T cells proliferated and specifically depleted
antigen-positive target cells in a mixed population. Importantly, all
responses were skewed toward Th1-biased immunity. In parallel,
Fig. 5. Antigen-specific killing activity of SARS-CoV-2 S-specific T cells. Kill-
ing assay using splenocytes of mice vaccinated on days 0 and 28 isolated 21 d
after the second immunization. Splenocytes were cocultured (A) with DC2.4
or (B) with antigen-presenting DC2.4-SARS2-S cells for 6 d. Activated CTLs
were then cocultured with EL-4green-SARS2-S target cells (Antigen) and EL-
4red control cells (NC) at indicated E:T ratios for 4 h. Ratio of living target to
nontarget cells (Antigen:NC) was determined by flow cytometry. Depicted
are means and SD of each group (open diamonds, MeVvac2-SARS2-S(H); filled
circles, mock; filled squares, MVvac2-ATU(P); gray triangles, S protein + Alum)
(n = 4 to 6). For statistical analysis, two-way ANOVA analysis was applied
with paired Tukey’s multicomparison test used as post hoc test. E:T, effector
cell : target cell ratio; ****P < 0.0001.
6 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.2014468117 Hörner et al.
the capacity to induce measles-specific immune reactivity remained
conserved. Finally, the induced immunity conferred protection in
two different animal models of SARS-CoV-2 infection, Syrian golden
hamsters inoculated with a low-passage patient isolate and mice
challenged with a mouse-adapted recombinant SARS-CoV-2 MA.
This effective MeV Moraten strain-derived recombinant vac-
cine MeVvac2-SARS2-S(H) is a live-attenuated vaccine that en-
codes the full-length, functional version of the SARS-CoV-2 S
protein as the main target for functional antibodies, but also for
induction of T cell responses. Vero cells revealed homogenous
expression of the SARS-CoV-2 S antigen by Western blot
analyses and positive immunostaining of syncytia after infection by
MeVvac2-SARS2-S(H). Stable antigen expression is a prerequisite
for the immune system to encounter the specific antigen to mount
robust immune responses and for industrial production of a vac-
cine. Indeed, IFNAR−/−-CD46Ge mice vaccinated with MeVvac2-
SARS2-S(H) in a prime−boost protocol showed uniform induc-
tion of antibodies directed against MeV bulk antigens or
SARS-CoV-2 S, which had considerable neutralizing activity
against both pathogens. We observe antibody responses in these
animals at a level that correlates with protection in mouse chal-
lenge models (14), as well as with neutralizing activity we found in
the serum of four reconvalescent human patients. These responses
were triggered despite the knockout of the type I IFN receptor,
which is necessary to allow propagation of MeV in mice (10,
15). This knockout usually should impair the induction of es-
pecially humoral immune responses (16). This highlights the
remarkable immunogenicity of the MeV vaccine platform
technology that also works in this model with partially impaired
immune responses.
However, why did not all immunized animals develop neu-
tralizing activity detectable in our assay? Firstly, determination
of the VNT relying on 100% pathogen neutralization is obviously
a rather harsh assay in the context of SARS-CoV-2, as evidenced
by the modest VNT titers published so far, in general, and ab-
sence of VNT in the S+Alum vaccinated group despite high
amounts of S-binding antibodies. This means that just detectable
VNT already indicates considerable neutralizing activity. Indeed,
when testing the sera of mice that were later on challenged with
SARS-CoV-2 MA in parallel for VNT and PRNT50 titers, two
animals negative for VNT became positive in PRNT50. Secondly,
we realized that three of the four animals which did not show a
VNT of >10 did not respond well to the prime vaccination, at all.
These animals developed no or only a minor VNT against MeV
after the first vaccination. This observation is rather unusual, and
argues for technical issues during the first vaccination in these
Fig. 6. Immune bias of induced responses. To analyze skewing of immune responses toward Th1- or Th2-biased immunity, (A) sera and (B) splenocytes of
vaccinated mice depicted before were analyzed. (A) Sera of mice vaccinated on days 0 and 28 with MeVvac2-SARS2-S(H) or Alum-adjuvanted S protein already
shown in Fig. 2 were analyzed for IgG1-or IgG2a-type antibodies specific for SARS-CoV-2 S. IgG1 (Left) or IgG2a (Right) binding to recombinant SARS-CoV S
were determined by ELISA via the specific optical density (OD) 450-nm value. Depicted are means and respective SD of the mean (SEM) of each group (n = 6 to
7). (B) Splenocytes of the same mice already shown in Figs. 3–5 and SI Appendix, Fig. S8 were analyzed by multiplex cytokine analysis for secretion of typical
marker cytokines in the supernatant after restimulation by coculture with antigen-presenting DC2.4-SARS2-S cells. DC2.4 cells served as nonspecific control
stimulus. Dots represent individual animals; horizontal bars are mean per group (n = 4 to 5). IFN-γ: upper limit of detection (ULOD): 2,015.2 pg/mL; IL-6: ULOD:
3,992.4 pg/mL; IL-17a lower limit of detection (LLOD): 0.473 pg/mL; IL-4 LLOD: 0.095 pg/mL; IL-5 LLOD: 0.685 pg/mL; IL-13 LLOD: 3.463 pg/mL. For statistical
analysis of grouped multiplex data, two-way ANOVA analysis was applied with paired Tukey’s multicomparison test as post hoc test. *P < 0.05; **P < 0.01;
***P < 0.001.









animals. Since none of the animals showed VNT against SARS-
CoV-2 after one vaccination with the vaccine, it is tempting to
speculate that a prime−boost protocol is associated, in this ani-
mal model, with maturation of antibodies to generate better
neutralizing responses. In hamsters, which fully responded to
each vaccination, all six MeVvac2-SARS2-S(H)−vaccinated ani-
mals developed VNT. On the other hand, all mice, including
the three improperly immunized ones, revealed significant,
multifunctional T cell responses against SARS-CoV-2 S, which
were still recordable 3 wk after the second vaccination, when we
already expect constriction of antigen-specific T cell effector
populations. These data suggest that anti-S antibody responses
mature after repeated vaccination, but, on the other hand, that a
one-shot vaccination regime will already induce especially func-
tional memory T cell immune responses, the protective efficacy
of which, as well as their duration, has to be demonstrated in
future challenge experiments. Moreover, anti-measles immunity
is generally stable (17) also after pediatric vaccination (18) and
might be a specific advantage of the measles vaccine platform
technology, which could transfer also to the additionally encoded
antigens.
Also, extended passaging of the vaccine candidate did not
result in changes of the vaccine, as revealed by sequencing of the
virus after 10 passages starting with a low multiplicity of infection
(MOI). This genetic stability indicates that the slight impairment
seen in multistep growth curves when compared to a vaccine-
strain MeV is not critical for the vaccine’s amplification and
therefore crucial for product safety. In accordance with its ge-
netic stability, the minor enhancement of fusion activity can also
be regarded as noncritical, especially when considering the fu-
sion activity of MeV used in clinical trials for treatment of tu-
mors. These so-called oncolytic MeV have been used in 15 phase
1 and phase 2 clinical trials, so far. Thereby, advanced-stage tumor
patients suffering from different tumor entities have been treated.
Despite constituting, in principle, a vulnerable patient collective,
application of high doses of nontargeted, fusion-active MeV (up
to 1 × 1011 TCID50) (19) systemically or, for example, directly
into the patients’ brains (20) was accompanied by an acceptable
safety profile (21). Therefore, the enhancement of fusion activity
cannot be expected to be crucial for product safety, while the
attenuation of vaccine-strain MeV is multifactorial, anyway, and
not just a matter of cell entry tropism and mechanism (22).
Likewise, the clinical phase 1 and 2 trials using the MeV vector
platform for the generation of bivalent vaccines, which induce
immunity against Chikungunya virus (CHIKV) (23, 24), have
revealed an extremely beneficial safety profile of this recombi-
nant vaccine concept also in human patients, while signs of ef-
ficacy became evident.
In any case, generation of MeV-derived COVID-19 vaccines
encoding a less fusion-active variant of the SARS-CoV-2 S gly-
coprotein might be beneficial to enhance titers of the vaccine
virus. In the meantime, stabilized S variants have become
available that have attenuated or no cell−cell fusion activity. One
variant has a deletion of the multibasic cleavage motif for furin-
like proteases at the S1/S2 boundary that facilitates preactivation
of S (25). A second variant has proline substitutions at residues
986 and 987, which are stabilizing a prefusion conformation of S
(26). Vaccine candidates encoding S with one of these motifs or
a combination thereof in a soluble version, as already done for
DNA vaccines (27), are under development. These have to show
an at least comparable capacity to induce neutralizing antibody
responses also in the context of MeV infection, which might be
dependent on the respective conformation of the antigen that is
expressed by vaccine virus-infected cells in situ.
Fig. 7. Vaccine efficacy in Syrian hamster and mouse challenge models. Fully immunized Syrian golden hamsters (A–D) and IFNAR−/−-CD46Ge mice (E) were
intranasally challenged with SARS-CoV-2 or mouse-adapted SARS-CoV-2 MA, respectively, and protection was analyzed by quantifying weight loss (A), live
virus titration in lungs or nasal turbinates (B), or SARS-2 E gene copy numbers via qRT-PCR (C and E). The limit of detection (LoD) is indicated. (D) For the
correlation analysis comparing humoral immunity (VNT) of hamsters vaccinated with MeVvac2-SARS2-S(H) on days 0 and 21 (sampled on day 35) and challenge
outcome, linear regression was performed with the indicated challenge outcome parameters to determine Pearson correlation coefficient (R2). For statistical
analysis of hamster data, one-way ANOVA was performed in combination with Tukey’s multicomparison test to compare all pair means. For comparison of
mouse data between the two groups, unpaired two-tailed t test was applied; ns, not significant; (P > 0.05); *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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The induction of the “right” antibodies and T cell responses is
especially crucial when taking potential complications into con-
sideration that can be observed when coronavirus encounters
“wrong” immune responses that can give rise to immunopa-
thologies after infection. In some infected cats, infection with
feline coronavirus causes feline infectious peritonitis, a deadly
disease characterized by viral infection of macrophages during
the acute phase. Interestingly, the switch of pathology after in-
fection from a rather moderate pathogenesis into an acute,
devastating disease can be triggered by vaccination of persis-
tently infected cats and has been attributed to the induction of
antibodies that mediate enhancement of the disease, a process
called ADE. During COVID-19, ADE might be the cause of the
severe cases currently observed. Some case reports indicate that
severe disease appeared more frequently in patients with high
SARS-CoV-2 IgG levels (28). ADE has been most prominent for
dengue virus (DENV) infections, especially in secondary infec-
tions with a different DENV serotype where enhancement of
disease correlated with the induction of nonneutralizing Abs that
can mediate an efficient uptake of the virus into FcR-positive
cells such as macrophages and other immune cells (29). More-
over, other immune-related adverse events were described for
SARS- and MERS-CoV. When animals were immunized with
vaccines that predominantly induce Th2-biased T-helper cell re-
sponses, vaccinated mice revealed significantly reduced virus loads
after challenge, but also an eosinophilic infiltrate into the lungs
accompanied by pathological changes of the lung tissue, so-called
ERD (30). Such immunopathologies upon CoV infection are a
major concern for diseases pathology and, especially, vaccine de-
velopment. Thus, Th2-biased immune responses as triggered by
alum-adjuvanted whole inactivated virus particles or recombinant
proteins should be avoided.
Interestingly, the live-attenuated MeV vaccine is known for a
balanced Th1/Th2 bias of induced immune responses, with a bias
for Th1 responses at least during the acute phase after vacci-
nation (31). In theory, this should also apply for immune re-
sponses induced against all antigens presented during an MeV
vaccine virus infection including foreign antigen(s) additionally
expressed when MeV is used as vaccine platform. Indeed, our
analyses provide evidence that the bias of the immune responses
is in favor of Th1 responses, as revealed by the inverted IgG1/
IgG2a subtype ratio of antibodies induced against SARS-CoV-2
S by MeVvac2-SARS2-S(H) compared to the animals immunized
with alum-adjuvanted recombinant S protein. Moreover, the cy-
tokine profile of splenocyte cultures of immunized mice after
restimulation of S-specific T cells reveals a respective preferable
Th1 bias. Since SARS-CoV-2 and SARS-CoV use the same pri-
mary attachment receptor for cell entry, hACE2, and selected
hACE2-transgenic mice show differential pathology after inocu-
lation with SARS-CoV-2 (14, 32), studying the impact of the Th1-
biased MeV-based immunization in hACE2-transgenic mice dur-
ing challenge with SARS-CoV-2 will be a matter for future studies.
In any case, our challenge data also reveal that MeV-derived
COVID-19 vaccines have a low likelihood to trigger immunopa-
thogenesis, but we show considerable antiviral efficacy, especially
in the Syrian hamster model. This animal model is susceptible
for SARS-CoV-2 infection and suitable for vaccination using
recombinant MeV (33); reveals in our setting a moderate to se-
vere, clearly distinguishable pathology; and shows airborne trans-
missibility from infected to naïve animals. Therefore, this animal
model accurately reflects at least some aspects of the course of
human disease and reveals the potential of our candidate to vac-
cinate effectively against COVID-19.
In conclusion, the bivalent MeV/SARS-CoV-2 vaccine candi-
date has a number of desirable properties with respect to its im-
munogenicity and efficacy against SARS-CoV-2. Furthermore, the
concurrent induction of anti-MeV immunity would allow its use in
the context of routine measles immunization schedules. Such an
MeV-based COVID-19 vaccine could be included in the currently
applied MMR (measles, mumps, rubella) vaccine, providing ad-
ditional protection against SARS-CoV-2. While there is contro-
versy regarding to what extent it occurs, children do become
infected and shed the virus, despite them rarely being severely af-
fected. In any case, preventing or reducing infection or virus
shedding from vaccinated children can also help to contain the
disease and protect vulnerable patient groups. On the other hand,
the vaccinated children themselves could be protected against
newly described side effects of COVID-19 infections, such as
Multisystem Inflammatory Syndrome, affecting also the cohort of
(very) young patients (34). Thereby, the capacity to produce large
amounts of vaccine doses as well as the respective distribution
network would be available more or less instantly from routine
measles vaccine production, but at no impairment of production of
other necessary vaccines, since the measles vaccine property is
preserved in the proposed vaccine candidate. Especially since
vaccination against the measles should not be impaired also during
the COVID-19 epidemic, this is a considerable advantage. Other-
wise, parallel epidemics with another, even more contagious re-
spiratory virus are looming when vaccination programs against the
measles are stopped in favor of COVID-19 vaccination programs.
However, while we envision primarily pediatric application for this
vaccine candidate, currently available data also suggest applicabil-
ity of MeV-derived recombinant bivalent vaccines also in vacci-
nees with preformed anti-measles immunity. The performance of
measles-derived recombinant vaccine targeting HIV-1 or CHIKV
has been analyzed in vivo in respective models in measles-
vaccinated animals. In both mice and nonhuman primates, at
least antibodies against the secondary target pathogen were suc-
cessfully induced also in preimmune animals (35, 36). This was
reflected by the outcome of phase I and phase II clinical studies of
an MeV-CHIKV vaccine candidate. Also, in human vaccinees,
induction of significant anti-CHIKV antibody titers independent
from the preimmunity seen in the respective individuals has been
observed (23, 24). Future studies have to demonstrate that this is
also the case for MeV-derived COVID-19 vaccine candidates.
Taken together, MeVvac2-SARS2-S(H) is a promising vaccine
candidate that warrants further investigation.
Materials and Methods
Detailed descriptions of the materials, methods, and equipment used in this
work, including cells, plasmids, production of lentiviral vectors and genera-
tion of antigen-expressing dendritic cell lines, viruses, MeV genome sequence
analysis, NGS library preparation and sequencing, RNA sequence analysis,
immunoperoxidase monolayer assay, Western blot analysis, animal experi-
ments, total IgG and IgG1-/IgG2a quantification, Th1/Th2 cytokine multiplex
assay, virus neutralization test, plaque reduction neutralization test, IFN-γ
ELISpot analysis, ICS, T cell proliferation assay, CTL killing assay, virus titers in
organs of infected animals, RNA preparation, quantitative RT-PCR, and sta-
tistical analyses, are provided in SI Appendix, Supplementary Extended
Materials and Methods.
Data Availability. All data are provided in the manuscript and SI Appendix.
The sequence data for the vaccine candidate described in this paper have
been deposited in the GenBank Data Bank (accession no. MW090971).
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